Samantha R. Keller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samantha R. Keller has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andreana N. Holowatyj
Vanderbilt University School of Medicine, Nashville, TN
7 shared publications - Hannah M. Seagle
Vanderbilt University Genetics Institute, Department of Medicine, Vanderbilt University, Nashville, TN, USA; Joseph Maxwell Cleland Atlanta VA Medical Center, Atlanta, GA, USA; Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
7 shared publications - Cathy Eng
Division of Hematology & Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37235, USA
6 shared publications - Digna R. Velez Edwards
Division of Quantitative and Clinical Sciences, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, USA
6 shared publications - José Perea
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy
6 shared publications - Mary Kay Washington
Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
6 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S5 and Figures S1-S4 from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Table S1. Clinical and demographic characteristics of the colorectal cancer (CRC) patient study population by race/ethnicity and age at sequencing: AACR Project GENIE.Table S2. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with early-onset and late-onset nonhypermutated colorectal cancer. Genes ranked by false discovery rate (FDR).Table S3. Racial/ethnic patterns in baseline mutation probability, comparison and heterogeneity of all non-silent somatic gene mutations among patients with early-onset and late-onset non-hypermutated colorectal cancer.Table S4. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with earlyonset and late-onset non-hypermutated colorectal cancer by sex.Table S5. Read depth for clinical-grade targeting sequencing data from tumor tissues and case counts by early-onset and late-onset groups and sequencing center. Figure S1. Mutation rates among 6,903 tumor samples from colorectal cancer patients across racial/ethnic groups.Figure S2. Adjusted mutation rates in 653 hypermutated colorectal tumors: AACR GENIE.Figure S3. Tumor mutational burden (TMB) across sequencing assay/platform for early-onset and late-onset non-hypermutated colorectal cancer cases: AACR Project GENIE.Figure S4. Frequency of non-silent somatic mutations in commonly assayed and mutated genes between early-onset and late-onset non-hypermutated CRC cases (mutation frequency >10%).
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S5 and Figures S1-S4 from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Table S1. Clinical and demographic characteristics of the colorectal cancer (CRC) patient study population by race/ethnicity and age at sequencing: AACR Project GENIE.Table S2. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with early-onset and late-onset nonhypermutated colorectal cancer. Genes ranked by false discovery rate (FDR).Table S3. Racial/ethnic patterns in baseline mutation probability, comparison and heterogeneity of all non-silent somatic gene mutations among patients with early-onset and late-onset non-hypermutated colorectal cancer.Table S4. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with earlyonset and late-onset non-hypermutated colorectal cancer by sex.Table S5. Read depth for clinical-grade targeting sequencing data from tumor tissues and case counts by early-onset and late-onset groups and sequencing center. Figure S1. Mutation rates among 6,903 tumor samples from colorectal cancer patients across racial/ethnic groups.Figure S2. Adjusted mutation rates in 653 hypermutated colorectal tumors: AACR GENIE.Figure S3. Tumor mutational burden (TMB) across sequencing assay/platform for early-onset and late-onset non-hypermutated colorectal cancer cases: AACR Project GENIE.Figure S4. Frequency of non-silent somatic mutations in commonly assayed and mutated genes between early-onset and late-onset non-hypermutated CRC cases (mutation frequency >10%).
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Molecular features underlying colorectal cancer disparities remain uncharacterized. Here, we investigated somatic mutation patterns by race/ethnicity and sex among 5,856 non-Hispanic white (NHW), 535 non-Hispanic Black (NHB), and 512 Asian/Pacific Islander (API) patients with colorectal cancer (2,016 early-onset colorectal cancer patients: sequencing age <50 years). NHB patients with early-onset nonhypermutated colorectal cancer, but not API patients, had higher adjusted tumor mutation rates than NHW patients. There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC, and PIK3CA mutation frequencies in early-onset nonhypermutated colorectal cancers between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4, and FAT1 between early-onset and late-onset nonhypermutated colorectal cancer. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2, and SMAD2. Males and females with nonhypermutated colorectal cancer had different trends in EP300 mutations by age group. These findings define genomic patterns of early-onset nonhypermutated colorectal cancer by race/ethnicity and sex, which yields novel biological clues into early-onset colorectal cancer disparities.Significance:NHBs, but not APIs, with early-onset nonhypermutated colorectal cancer had higher adjusted tumor mutation rates versus NHWs. Differences for FLT4, FBXW7, RNF43, LRP1B, APC, PIK3CA, and ATRX mutation rates between racial/ethnic groups and EP300, KRAS, AXIN2, WRN, BRAF, and LRP1B mutation rates by sex were observed in tumors of young patients.See related commentary by Shen et al., p. 530.This article is highlighted in the In This Issue feature, p. 517
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Molecular features underlying colorectal cancer disparities remain uncharacterized. Here, we investigated somatic mutation patterns by race/ethnicity and sex among 5,856 non-Hispanic white (NHW), 535 non-Hispanic Black (NHB), and 512 Asian/Pacific Islander (API) patients with colorectal cancer (2,016 early-onset colorectal cancer patients: sequencing age <50 years). NHB patients with early-onset nonhypermutated colorectal cancer, but not API patients, had higher adjusted tumor mutation rates than NHW patients. There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC, and PIK3CA mutation frequencies in early-onset nonhypermutated colorectal cancers between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4, and FAT1 between early-onset and late-onset nonhypermutated colorectal cancer. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2, and SMAD2. Males and females with nonhypermutated colorectal cancer had different trends in EP300 mutations by age group. These findings define genomic patterns of early-onset nonhypermutated colorectal cancer by race/ethnicity and sex, which yields novel biological clues into early-onset colorectal cancer disparities.Significance:NHBs, but not APIs, with early-onset nonhypermutated colorectal cancer had higher adjusted tumor mutation rates versus NHWs. Differences for FLT4, FBXW7, RNF43, LRP1B, APC, PIK3CA, and ATRX mutation rates between racial/ethnic groups and EP300, KRAS, AXIN2, WRN, BRAF, and LRP1B mutation rates by sex were observed in tumors of young patients.See related commentary by Shen et al., p. 530.This article is highlighted in the In This Issue feature, p. 517
- 10 September 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (26) , 4279-4289
Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer
PURPOSE: The early-onset colorectal cancer (EOCRC) burden differs across racial/ethnic groups, yet the role of germline genetic predisposition in EOCRC disparities remains uncharacterized. We defined the prevalence and spectrum of inherited colorectal cancer (CRC) susceptibility gene variations among patients with EOCRC by race and ethnicity. PATIENTS AND METHODS: We included individuals diagnosed with a first primary CRC between age 15 and 49 years who identified as Ashkenazi Jewish, Asian, Black, Hispanic, or White and underwent germline genetic testing of 14 CRC susceptibility genes performed by a clinical testing laboratory. Variant comparisons by racial and ethnic groups were evaluated using chi-square tests and multivariable logistic regression adjusted for sex, age, CRC site, and number of primary colorectal tumors. RESULTS: Among 3,980 patients with EOCRC, a total of 530 germline pathogenic or likely pathogenic variants were identified in 485 individuals (12.2%). By race/ethnicity, 12.7% of Ashkenazim patients, 9.5% of Asian patients, 10.3% of Black patients, 14.0% of Hispanic patients, and 12.4% of White patients carried a germline variant. The prevalence of Lynch syndrome ( P = .037), as well as APC, CHEK2, MLH1, monoallelic MUTYH, and PTEN variants, varied by race/ethnicity among patients with EOCRC (all P < .026). Ashkenazim and Hispanic patients had significantly higher odds of presenting with a pathogenic APC variant, which included p.I1307K (odds ratio [OR], 2.67; 95% CI, 1.30 to 5.49; P = .007) and MLH1 variant (OR, 8.69; 95% CI, 2.68 to 28.20; P = .0003), respectively, versus White patients in adjusted models. CONCLUSION: Germline genetic features differed by race/ethnicity in young patients with CRC, suggesting that current multigene panel tests may not be representative of EOCRC risk in diverse populations. Further study is needed to optimize genes selected for genetic testing in EOCRC via ancestry-specific gene and variant discovery to yield equitable clinical benefits for all patients and to mitigate inequities in disease burden.
- 10 September 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (26) , 4279-4289
Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer
PURPOSE: The early-onset colorectal cancer (EOCRC) burden differs across racial/ethnic groups, yet the role of germline genetic predisposition in EOCRC disparities remains uncharacterized. We defined the prevalence and spectrum of inherited colorectal cancer (CRC) susceptibility gene variations among patients with EOCRC by race and ethnicity. PATIENTS AND METHODS: We included individuals diagnosed with a first primary CRC between age 15 and 49 years who identified as Ashkenazi Jewish, Asian, Black, Hispanic, or White and underwent germline genetic testing of 14 CRC susceptibility genes performed by a clinical testing laboratory. Variant comparisons by racial and ethnic groups were evaluated using chi-square tests and multivariable logistic regression adjusted for sex, age, CRC site, and number of primary colorectal tumors. RESULTS: Among 3,980 patients with EOCRC, a total of 530 germline pathogenic or likely pathogenic variants were identified in 485 individuals (12.2%). By race/ethnicity, 12.7% of Ashkenazim patients, 9.5% of Asian patients, 10.3% of Black patients, 14.0% of Hispanic patients, and 12.4% of White patients carried a germline variant. The prevalence of Lynch syndrome ( P = .037), as well as APC, CHEK2, MLH1, monoallelic MUTYH, and PTEN variants, varied by race/ethnicity among patients with EOCRC (all P < .026). Ashkenazim and Hispanic patients had significantly higher odds of presenting with a pathogenic APC variant, which included p.I1307K (odds ratio [OR], 2.67; 95% CI, 1.30 to 5.49; P = .007) and MLH1 variant (OR, 8.69; 95% CI, 2.68 to 28.20; P = .0003), respectively, versus White patients in adjusted models. CONCLUSION: Germline genetic features differed by race/ethnicity in young patients with CRC, suggesting that current multigene panel tests may not be representative of EOCRC risk in diverse populations. Further study is needed to optimize genes selected for genetic testing in EOCRC via ancestry-specific gene and variant discovery to yield equitable clinical benefits for all patients and to mitigate inequities in disease burden.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S5 and Figures S1-S4 from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Table S1. Clinical and demographic characteristics of the colorectal cancer (CRC) patient study population by race/ethnicity and age at sequencing: AACR Project GENIE.Table S2. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with early-onset and late-onset nonhypermutated colorectal cancer. Genes ranked by false discovery rate (FDR).Table S3. Racial/ethnic patterns in baseline mutation probability, comparison and heterogeneity of all non-silent somatic gene mutations among patients with early-onset and late-onset non-hypermutated colorectal cancer.Table S4. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with earlyonset and late-onset non-hypermutated colorectal cancer by sex.Table S5. Read depth for clinical-grade targeting sequencing data from tumor tissues and case counts by early-onset and late-onset groups and sequencing center. Figure S1. Mutation rates among 6,903 tumor samples from colorectal cancer patients across racial/ethnic groups.Figure S2. Adjusted mutation rates in 653 hypermutated colorectal tumors: AACR GENIE.Figure S3. Tumor mutational burden (TMB) across sequencing assay/platform for early-onset and late-onset non-hypermutated colorectal cancer cases: AACR Project GENIE.Figure S4. Frequency of non-silent somatic mutations in commonly assayed and mutated genes between early-onset and late-onset non-hypermutated CRC cases (mutation frequency >10%).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S5 and Figures S1-S4 from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Table S1. Clinical and demographic characteristics of the colorectal cancer (CRC) patient study population by race/ethnicity and age at sequencing: AACR Project GENIE.Table S2. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with early-onset and late-onset nonhypermutated colorectal cancer. Genes ranked by false discovery rate (FDR).Table S3. Racial/ethnic patterns in baseline mutation probability, comparison and heterogeneity of all non-silent somatic gene mutations among patients with early-onset and late-onset non-hypermutated colorectal cancer.Table S4. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with earlyonset and late-onset non-hypermutated colorectal cancer by sex.Table S5. Read depth for clinical-grade targeting sequencing data from tumor tissues and case counts by early-onset and late-onset groups and sequencing center. Figure S1. Mutation rates among 6,903 tumor samples from colorectal cancer patients across racial/ethnic groups.Figure S2. Adjusted mutation rates in 653 hypermutated colorectal tumors: AACR GENIE.Figure S3. Tumor mutational burden (TMB) across sequencing assay/platform for early-onset and late-onset non-hypermutated colorectal cancer cases: AACR Project GENIE.Figure S4. Frequency of non-silent somatic mutations in commonly assayed and mutated genes between early-onset and late-onset non-hypermutated CRC cases (mutation frequency >10%).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S5 and Figures S1-S4 from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Table S1. Clinical and demographic characteristics of the colorectal cancer (CRC) patient study population by race/ethnicity and age at sequencing: AACR Project GENIE.Table S2. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with early-onset and late-onset nonhypermutated colorectal cancer. Genes ranked by false discovery rate (FDR).Table S3. Racial/ethnic patterns in baseline mutation probability, comparison and heterogeneity of all non-silent somatic gene mutations among patients with early-onset and late-onset non-hypermutated colorectal cancer.Table S4. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with earlyonset and late-onset non-hypermutated colorectal cancer by sex.Table S5. Read depth for clinical-grade targeting sequencing data from tumor tissues and case counts by early-onset and late-onset groups and sequencing center. Figure S1. Mutation rates among 6,903 tumor samples from colorectal cancer patients across racial/ethnic groups.Figure S2. Adjusted mutation rates in 653 hypermutated colorectal tumors: AACR GENIE.Figure S3. Tumor mutational burden (TMB) across sequencing assay/platform for early-onset and late-onset non-hypermutated colorectal cancer cases: AACR Project GENIE.Figure S4. Frequency of non-silent somatic mutations in commonly assayed and mutated genes between early-onset and late-onset non-hypermutated CRC cases (mutation frequency >10%).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S5 and Figures S1-S4 from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Table S1. Clinical and demographic characteristics of the colorectal cancer (CRC) patient study population by race/ethnicity and age at sequencing: AACR Project GENIE.Table S2. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with early-onset and late-onset nonhypermutated colorectal cancer. Genes ranked by false discovery rate (FDR).Table S3. Racial/ethnic patterns in baseline mutation probability, comparison and heterogeneity of all non-silent somatic gene mutations among patients with early-onset and late-onset non-hypermutated colorectal cancer.Table S4. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with earlyonset and late-onset non-hypermutated colorectal cancer by sex.Table S5. Read depth for clinical-grade targeting sequencing data from tumor tissues and case counts by early-onset and late-onset groups and sequencing center. Figure S1. Mutation rates among 6,903 tumor samples from colorectal cancer patients across racial/ethnic groups.Figure S2. Adjusted mutation rates in 653 hypermutated colorectal tumors: AACR GENIE.Figure S3. Tumor mutational burden (TMB) across sequencing assay/platform for early-onset and late-onset non-hypermutated colorectal cancer cases: AACR Project GENIE.Figure S4. Frequency of non-silent somatic mutations in commonly assayed and mutated genes between early-onset and late-onset non-hypermutated CRC cases (mutation frequency >10%).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Molecular features underlying colorectal cancer disparities remain uncharacterized. Here, we investigated somatic mutation patterns by race/ethnicity and sex among 5,856 non-Hispanic white (NHW), 535 non-Hispanic Black (NHB), and 512 Asian/Pacific Islander (API) patients with colorectal cancer (2,016 early-onset colorectal cancer patients: sequencing age <50 years). NHB patients with early-onset nonhypermutated colorectal cancer, but not API patients, had higher adjusted tumor mutation rates than NHW patients. There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC, and PIK3CA mutation frequencies in early-onset nonhypermutated colorectal cancers between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4, and FAT1 between early-onset and late-onset nonhypermutated colorectal cancer. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2, and SMAD2. Males and females with nonhypermutated colorectal cancer had different trends in EP300 mutations by age group. These findings define genomic patterns of early-onset nonhypermutated colorectal cancer by race/ethnicity and sex, which yields novel biological clues into early-onset colorectal cancer disparities.Significance:NHBs, but not APIs, with early-onset nonhypermutated colorectal cancer had higher adjusted tumor mutation rates versus NHWs. Differences for FLT4, FBXW7, RNF43, LRP1B, APC, PIK3CA, and ATRX mutation rates between racial/ethnic groups and EP300, KRAS, AXIN2, WRN, BRAF, and LRP1B mutation rates by sex were observed in tumors of young patients.See related commentary by Shen et al., p. 530.This article is highlighted in the In This Issue feature, p. 517
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Molecular features underlying colorectal cancer disparities remain uncharacterized. Here, we investigated somatic mutation patterns by race/ethnicity and sex among 5,856 non-Hispanic white (NHW), 535 non-Hispanic Black (NHB), and 512 Asian/Pacific Islander (API) patients with colorectal cancer (2,016 early-onset colorectal cancer patients: sequencing age <50 years). NHB patients with early-onset nonhypermutated colorectal cancer, but not API patients, had higher adjusted tumor mutation rates than NHW patients. There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC, and PIK3CA mutation frequencies in early-onset nonhypermutated colorectal cancers between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4, and FAT1 between early-onset and late-onset nonhypermutated colorectal cancer. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2, and SMAD2. Males and females with nonhypermutated colorectal cancer had different trends in EP300 mutations by age group. These findings define genomic patterns of early-onset nonhypermutated colorectal cancer by race/ethnicity and sex, which yields novel biological clues into early-onset colorectal cancer disparities.Significance:NHBs, but not APIs, with early-onset nonhypermutated colorectal cancer had higher adjusted tumor mutation rates versus NHWs. Differences for FLT4, FBXW7, RNF43, LRP1B, APC, PIK3CA, and ATRX mutation rates between racial/ethnic groups and EP300, KRAS, AXIN2, WRN, BRAF, and LRP1B mutation rates by sex were observed in tumors of young patients.See related commentary by Shen et al., p. 530.This article is highlighted in the In This Issue feature, p. 517
- 15 December 2022
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (3) , 570-579
Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Molecular features underlying colorectal cancer disparities remain uncharacterized. Here, we investigated somatic mutation patterns by race/ethnicity and sex among 5,856 non-Hispanic white (NHW), 535 non-Hispanic Black (NHB), and 512 Asian/Pacific Islander (API) patients with colorectal cancer (2,016 early-onset colorectal cancer patients: sequencing age <50 years). NHB patients with early-onset nonhypermutated colorectal cancer, but not API patients, had higher adjusted tumor mutation rates than NHW patients. There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC, and PIK3CA mutation frequencies in early-onset nonhypermutated colorectal cancers between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4, and FAT1 between early-onset and late-onset nonhypermutated colorectal cancer. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2, and SMAD2. Males and females with nonhypermutated colorectal cancer had different trends in EP300 mutations by age group. These findings define genomic patterns of early-onset nonhypermutated colorectal cancer by race/ethnicity and sex, which yields novel biological clues into early-onset colorectal cancer disparities. Significance: NHBs, but not APIs, with early-onset nonhypermutated colorectal cancer had higher adjusted tumor mutation rates versus NHWs. Differences for FLT4, FBXW7, RNF43, LRP1B, APC, PIK3CA, and ATRX mutation rates between racial/ethnic groups and EP300, KRAS, AXIN2, WRN, BRAF, and LRP1B mutation rates by sex were observed in tumors of young patients. See related commentary by Shen et al., p. 530 . This article is highlighted in the In This Issue feature, p. 517
- 15 December 2022
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (3) , 570-579
Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer
Molecular features underlying colorectal cancer disparities remain uncharacterized. Here, we investigated somatic mutation patterns by race/ethnicity and sex among 5,856 non-Hispanic white (NHW), 535 non-Hispanic Black (NHB), and 512 Asian/Pacific Islander (API) patients with colorectal cancer (2,016 early-onset colorectal cancer patients: sequencing age <50 years). NHB patients with early-onset nonhypermutated colorectal cancer, but not API patients, had higher adjusted tumor mutation rates than NHW patients. There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC, and PIK3CA mutation frequencies in early-onset nonhypermutated colorectal cancers between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4, and FAT1 between early-onset and late-onset nonhypermutated colorectal cancer. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2, and SMAD2. Males and females with nonhypermutated colorectal cancer had different trends in EP300 mutations by age group. These findings define genomic patterns of early-onset nonhypermutated colorectal cancer by race/ethnicity and sex, which yields novel biological clues into early-onset colorectal cancer disparities. Significance: NHBs, but not APIs, with early-onset nonhypermutated colorectal cancer had higher adjusted tumor mutation rates versus NHWs. Differences for FLT4, FBXW7, RNF43, LRP1B, APC, PIK3CA, and ATRX mutation rates between racial/ethnic groups and EP300, KRAS, AXIN2, WRN, BRAF, and LRP1B mutation rates by sex were observed in tumors of young patients. See related commentary by Shen et al., p. 530 . This article is highlighted in the In This Issue feature, p. 517